Tag: CD25
ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...
This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...
15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...
During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...
First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...
A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...
Updates from the 14th International Conference on Malignant Lymphoma (ICML)
Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...
ADC Therapeutics Raises US$ 80 million to Advance ADC Pipeline
ADC Therapeutics, an oncology drug discovery and development company headquartered in Lausanne, Switzerland and London, UK, that specializes in the development of proprietary Antibody...
Antigen Shedding and Targeted Delivery of Immunotoxins in Solid Tumors: A...
Cells modulate responses to signals in the extracellular environment by shedding cell surface antigens. Understanding this process is important because antibody-based anti-cancer therapies target...
ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate
Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...
